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Abstract
The vast majority of glomerular filtrated phosphate is reabsorbed in the proximal tubule. Posttransplant phosphaturia is
common and aggravated by sirolimus immunosuppression. The cause of sirolimus induced phosphaturia however remains
elusive. Male Wistar rats received sirolimus or vehicle for 2 or 7 days (1.5mg/kg). The urine phosphate/creatinine ratio was
higher and serum phosphate was lower in sirolimus treated rats, fractional excretion of phosphate was elevated and renal
tubular phosphate reabsorption was reduced suggesting a renal cause for hypophosphatemia. PTH was lower in sirolimus
treated rats. FGF 23 levels were unchanged at day 2 but lower in sirolimus treated rats after 7 days. Brush border membrane
vesicle phosphate uptake was not altered in sirolimus treated groups or by direct incubation with sirolimus. mRNA, protein
abundance, and subcellular transporter distribution of NaPi-IIa, Pit-2 and NHE3 were not different between groups but NaPi-
IIc mRNA expression was lower at day 7. Transcriptome analyses revealed candidate genes that could be involved in the
phosphaturic response. Sirolimus caused a selective renal phosphate leakage, which was not mediated by NaPi-IIa or NaPi-
IIc regulation or localization. We hypothesize that another mechanism such as a basolateral phosphate transporter may be
responsible for the sirolimus induced phosphaturia.
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Introduction
Inorganic phosphate (Pi) is an essential nutrient involved in
various life-sustaining processes such as cell metabolism and
skeletal mineralization. The kidney is the major regulator of
extracellular phosphate homeostasis. Phosphate is freely filtered in
the glomerulus and mostly reabsorbed along the proximal tubule
(PT) according to the organisms’ needs to maintain a balanced
serum phosphate. To date, three distinct sodium dependent
phosphate cotransporter with a pivotal role for phosphate
reabsorption in the kidney have been identified in the brush
border membrane (BBM) of proximal tubule cells: NaPi-IIa
(SLC34A1), NaPi-IIc (SLC343) and Pit-2 (SLC20A2) [1–6]. These
transporters are regulated by a variety of factors and hormones
including parathyroid hormone (PTH), 1,25-(OH)2-vitamin D3,
and fibroblast growth factor 23 (FGF23) [4]. In the context of
renal transplantation phosphate homeostasis is often disturbed and
severe hypophosphatemia is a common and potential life-
threatening problem during the first weeks after engraftment [7].
The preceding hyperparathyroidism and delayed reduction in
FGF23 levels in patients suffering from chronic kidney disease can
only partially explain reduced serum phosphate levels after kidney
transplantation [8–10]. To date it is not fully understood to which
extent immunosuppressive regimens further contribute to post-
transplant hypophosphatemia. In fact several reports demonstrate
the influence of various immunosuppressants including glucocor-
ticoids, cyclosporine and tacrolimus on phosphate reabsorption in
vivo [11–13]. Moreover, we have recently observed an aggravated
and prolonged renal phosphate wasting after renal transplantation
in recipients receiving sirolimus-based immunosuppression com-
pared to patients on sirolimus-free immunosuppression [14].
Sirolimus is a potent inhibitor of the mammalian target of
rapamycin (mTOR) and routinely used after solid organ trans-
plantation to prevent rejection. mTOR has long been known for
its pivotal role in regulating cell proliferation and cell growth.
More recently it has been shown in the heterologous Xenopus
oocyte expression system to be involved in the regulation of
various solute carrier such as the creatinine transporter SLC6A8
and the renal and intestinal sodium dependent phosphate
cotransporters NaPi-IIa (SLC334A1) and NaPi-IIb (SLC34A2)
[15–17]. Furthermore it has been demonstrated that the
stimulating effect of mTOR on NaPi-IIa and NaPi-IIb is
suppressed by sirolimus [16,17]. However, detailed mechanisms
how sirolimus might affect renal phosphate reabsorption remain
unidentified until today. The present study aimed to elucidate the
underlying mechanisms involved in sirolimus induced renal
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phosphate loss. We hypothesized that sirolimus suppresses sodium
dependent phosphate reabsorption in the PT and therefore tested
for a potential role of sirolimus in the regulation of renal phosphate
transport across the PT mediated by NaPi-IIa, NaPi-IIc, and Pit-2.
Material And Methods
Animals
Male Wistar rats (120–150 g, Charles River, Germany) were
randomly divided into four groups: groups 1 and 3 received
vehicle, groups 2 and 4 sirolimus. Each group consisted of six
animals and we used samples from each rat for all experiments.
Daily subcutaneous injections of sirolimus (1.5 mg/kg body
weight) were given for either 2 days (group 2) or seven days
(group 4), whereas control animals received daily injections of
vehicle for either two days (group 1) or seven days (group 3).
Sirolimus (Sigma Aldrich, Germany) was dissolved in polyethylene
glycol 400, 10% polysorbat 80 and 20% dimethylacetamid.
Vehicle consisted of the three solvents. Rats were maintained on
a standard rodent chow containing 0.8% phosphate (Kliba AG,
Kaiseraugst, Switzerland) and had access to drinking water ad
libitum. All animals were placed in individual metabolic cages for
three and eight days, respectively, allowing a 24 hour adaption
period to the metabolic cage environment. Food and water
consumption, body weight, stool and urine output were monitored
daily. Urine samples were collected daily under mineral oil. All
animal experiments were performed according to national and
international guidelines and laws of animal welfare. Protocols were
approved by the local veterinary authorities (Veterinaeramt
Zurich 11/2010, Bundesministerium fu¨r Wissenschaft und For-
schung O¨sterreich 66009/4-II/10b/2010).
Blood and Urine Analysis
At the end of the experiments rats were anesthetized by
inhalation of Isoflurane/air and heparinized arterial blood was
collected from the tail artery and immediately analyzed for pH,
blood gases, and electrolytes on a Radiometer ABL 800 Flex blood
gas analyzer (Radiometer, Copenhagen, Denmark). Serum creat-
inine, serum phosphate and serum glucose concentrations were
determined using the clinical chemistry analyzer Piccolo Xpress
(LabForce, Nunningen, Switzerland). Vitamin D plasma levels
were determined using the 1,25 Dihydroxy Vitamin D RIA
(Immunodiagnostic Systems Ltd., Baldon, UK) according to the
Table 1. Blood and urine parameters from vehicle and sirolimus-treated rats after two and seven days of treatment.
2d 7d
Vehicle Sirolimus Vehicle Sirolimus
Body weight at start (g) 245.5611.5 249.4613.3 191.363.8 184.163.4
Body weight after treatment (g) 225.466.7 215.6610.2 238.265.9 195.765.1{
Blood
pH 7.4160.01 7.4560.01 7.4360.006 7.4260.01
PCO2 (mmHg) 37.261.6 38.861.5 36.261.0 37.661.7
HCO32 (mmol/l) 24.360.8 26.560.6 24.862.2 24.760.6
Na+ (mmol/l) 142.061.9 143.261.2 140.760.9 140.760.8
K+ (mmol/l) 4.660.2 3.460.06{ 4.360.3 3.460.2
Cl2 (mmol/l) 9661.5 9863.6 94.363.0 93.261.9
Calcium (mmol/l) 2.660.07 2.660.03 2.660.02 2.560.04
Phosphate (mmol/l) 3.360.09 2.860.05{ 3.060.08 2.460.09{
Creatinine (mmol/l) 17.760.1 19.261.5 22.163.0 17.760.1
Glucose (mmol/l) 10.060.7 10.160.7 8.960.3 15.361.5{
Sirolimus trough level (mg/l) 0 20.962.8 0 19.664.5
Urine
24-h Urine/body weight (ml/g) 0.0360.002 0.0660.006* 0.0360.004 0.1260.03*
pH 6.1460.06 6.2060.06 6.3460.05 6.1060.09*
Osmolarity (mOsmol/kg) 13256340 15846313 11896217 16756250*
Creatinine Clearance (ml/min) 2.360.1 2.160.2 2.160.3 1.960.2
P2/Creatinine (mmol/l)/(mmol/l) 12.460.6 17.860.7{ 10.461.1 15.860.9{
TmP/GFR (mmol/l) 3.060.1 2.560.06{ 2.860.06 2.160.09{
Na+/Creatinine (mmol/l)/(mmol/l) 13.262.3 18.664.4* 15.761.1 21.564.2*
K+/Creatinine (mmol/l)/(mmol/l) 49.766.6 51.863.0 48.762.8 48.764.2
Cl2/Creatinine (mmol/l)/(mmol/l) 29.264.1 33.262.7 29.262.7 39.665.9{
Mg2+/Creatinine (mmol/l)/(mmol/l) 3.061.3 4.860.8* 3.661.2 4.960.4*
Ca2+/Creatinine (mmol/l)/(mmol/l) 0.460.1 1.060.4{ 0.560.1 1.760.8*
HCO3
2/Creatinine (mmol/l)/(mmol/l) 0.260.05 0.2960.05 0.8560.4 1.6960.4
Values are means 6 SE, n = 6/group. A summary of blood and urine parameters from rats treated with vehicle and sirolimus for two and seven days is shown. *p,0.05.
{p,0.01. {p,0.001.
doi:10.1371/journal.pone.0039229.t001
Sirolimus Induced Phosphaturia
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manufacture’s protocol. The levels of intact fibroblast growth
factor 23 (intact FGF23, Kainos Laboratories Inc., Tokyo, Japan)
intact parathyroid hormone (intact PTH, Immunotopics Inc., San
Clemente CA, USA) and soluble klotho (Immuno-Biological
Labratories Co., Minneapolis, USA) were measured by a two-site
enzyme-linked immunosorbent assay in rodent serum samples,
according to the manufacturer’s protocol. Inter-assay and intra-
assay coefficients of variation were below 5% for all laboratory
analyses. Creatinine clearance was calculated from the measured
values. Sirolimus blood levels were measured using HPLC-mass
spectrometry [18]. For urinary pH, PCO2 and calculated HCO3
2
measurement urine was aspirated from the collectors (urine was
collected under mineral oil) into syringes and injected into the
blood gas analyzer. Urinary creatinine was analyzed using the
Jaffe´ method [19]. Urinary phosphate was determined by endpoint
method with sample blanking [19,20]. Urinary K+, Na+, Cl,2
Ca2+ and Mg2+ concentrations were measured using a chemistry
analyzer (Cobas Integra 800, Roche, Urinary osmolarity was
determined using a One-Ten Osmometer (Fiske Associates,
Norwood, Massachussettes, USA) by examination of freezing-
point depression. A test for low molecular weight proteinuria was
performed. Urine samples were normalized for creatinine and
samples containing 10 mg creatinine were then solubilized in
Laemmli sample buffer and SDS-PAGE was performed on a 15%
polyacrylamid gel. Colloidal coomassie blue staining was per-
formed for 1h at room temperature. After destaining for 2h, the
gel was photographed and dried. Five micrograms of BSA served
as a positive control.
RNA extraction and semi-quantitative real time qRT-PCR
Total RNA from kidneys was extracted using the Qiagen
RNeasy Mini Kit (Qiagen, Hombrechtikon, Switzerland). Snap-
frozen kidneys were homogenized in RLT buffer (Qiagen)
Figure 1. Effect of sirolimus on renal phosphate excretion.
Trajectories of urinary phosphate/creatinine ratios of sirolimus and
vehicle treated rats. Sirolimus caused statistically significant increased
urinary phosphate excretion 24 hours after the first sirolimus injection
(day 2) until after seven sirolimus injection (day 8, n = 6 for each group).
doi:10.1371/journal.pone.0039229.g001
Figure 2. Sirolimus has no effect on apical renal phosphate transport. Effect of Sirolimus treatment for two and seven days on BBM sodium-
dependent phosphate uptake in absence and presence of phosphonoformic acid (6 mM, PFA), an inhibitor of SLC34 phosphate cotransporter.
Sirolimus did not alter 32Pi-uptake in absence (a) or presence (b) of PFA after two and seven days of sirolimus treatment (n = 6 each group).
Incubation of BBMV from untreated rats with 20ng/ml and 100ng/ml sirolimus did not change Na+-dependent phosphate fluxes in the absence (c) or
presence (d) of PFA.
doi:10.1371/journal.pone.0039229.g002
Sirolimus Induced Phosphaturia
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supplemented with ß-mercaptoethanol to a final concentration of
1%. Subsequently, 200 ml of each homogenate were used for total
RNA isolation according to the manufacturer’s protocol. DNAse
digestion was performed using the RNase-free DNAase set
(Qiagen, Hilden, Germany). Quality and concentration of the
isolated RNA preparations were analyzed spectroscopically using
the 2100 Bioanalyzer (Agilent Technologies) and the NanoDrop
ND-1000 spectrophotometer (NanoDrop Technologies). RNA
samples were diluted to a final concentration of 100 ng/ml and
3 ml were used for cDNA preparation using the TaqMan Reverse
Transcriptase Reagent Kit (Applied Biosystems/Roche, Foster
City, CA). Primers and probes (Microsynth, Balgach, Switzerland)
of all genes of interest were designed using Primer Express
Software (v.2.0.; Applied Biosystems), and primers were tested by
PCR with kidney cDNA and always resulted in a single product of
the expected size (data not shown). Sequences of primers and
probes are listed in Data S1. Real-time PCR reactions were
performed using the TaqMan Universal PCR Master Mix
(Applied Biosystems). Briefly, 3 ml cDNA, 0.8 ml of each primer
(25 mM) and 0.4 ml of labeled probe (5 mM), 5 ml RNase-free
water, 1 0ml TaqMan Universal PCR Master Mix added to a final
volume of 20 ml. Reactions were run in 96-well optical reaction
plates using the Prism 7500 fast Real-Time PCR cycler. Cycling
conditions were set to one cycle for 2 min at 50uC, 10 min at
95uC, followed by 40 cycles at 95uC (10s) and 60uC (1 min) with
auto ramp time. All reactions were run in triplicate, and one
negative control without addition of the multiscribe reverse
transcription enzyme was included for each sample. The relative
abundance of target mRNA was calculated to a reference mRNA
(hypoxanthine-guanine-phosphoribosyltransferase; HPRT). Rela-
tive expression levels were calculated as R= 2[Ct(HPRT) _ Ct(gene)],
where Ct is the cycle number at which the fluorescence intensity is
above background levels (threshold).
Brush border membrane vesicle preparation and
phosphate uptake experiments
Frozen kidneys were used to prepare total membrane proteins
and brush border membrane vesicle (BBMV) using the Mg2+
precipitation technique as previously described [21,22]. The
phosphate transport rate into BBMV was measured in freshly
prepared BBMV at 25uC in the presence of inward gradients of
100 mM NaCl or 100 mM KCl and 0.1 mM K-phosphate. The
substrate Pi was made with 0.125 mM K2HPO4 and 32P (1mCi/
ml) to give a final concentration 0.1 mM close to the expected
apparent Km for Pi for Na+-dependent transport in renal BBMV.
The stop solution contained 100 mM Mannitol, 5 mM Tris–HCl
pH 7.4, 150 mM NaCl, 5 mM Pi. Na+-dependence was estab-
lished by incubating BBMV in solutions in which KCl replaced
NaCl equimolarly. Phosphate uptake was determined after 60 s,
representing initial linear conditions, and after 120 min, to
determine the equilibrium values. In order to distinguish between
Na+-dependent Pi uptake mediated by SLC34 family members
(e.g., NaPi-IIa and NaPi-IIc) and other Na+-dependent phosphate
transporters such as SLC20 family members (e.g., Pit-1 and Pit-2),
we used trisodium phosphonoformic acid (PFA, final concentra-
tion 6 mM) added to the same solution with 107mM NaCl. PFA is
known to be an inhibitor of BBMV phosphate uptake since
decades [23,24] but has previously been shown to have a higher
selectivity for type II (i.e. NaPi-IIa and NaPi-IIc, SLC34) than type
III (i.e. Pit-2, SLC20) phosphate transporters at these concentra-
tions [2,25–27]. Total protein concentration was measured using
the Bio-Rad Protein Assay kit, Bio-Rad, Hercules, CA, USA.
BBMV were stored at 280uC until further use.
Immunoblotting
Ten micrograms of renal BBM protein or 35mg of total
membrane protein was solubilized in Laemmli sample buffer and
SDS-PAGE was performed on 8% polyacrylamid gels. Proteins
were transferred electrophoretically from gels to polyvinylidene
difluoride membranes (Immobilon-P, Millipore, Bedford, MA).
After blocking with 5% milk powder in tris-buffered saline
containing 0.1% tween 20 for 60min, the blots were incubated
with the respective primary antibodies: rabbit polyclonal anti-
NaPi-IIa (1:6,000) [28], rabbit polyclonal anti-NaPi-IIc (1:10,000)
[29], rabbit polyclonal anti-Pit-2 (1:3,000) (kindly provided by V.
Sorribas, University of Zaragosa, Spain), rabbit polyclonal anti
NHE3 (1:5,000)(generated by immunization of rabbits with
a peptide linked to KLH, Pineda antibody service, Berlin,
Germany) rabbit polyclonal anti-klotho (Abcam, Cambridge,
UK) and mouse monoclonal anti-b-actin antibody (42kD; Sigma,
St. Louis, MO; 1:5,000) overnight at 4uC. After washing and
subsequent blocking, blots were incubated with the secondary
antibody (donkey anti-rabbit or sheep anti-mouse antibodies
linked to horseradish peroxidase 1:10,000, (GE Healthcare, Little
Chalfont, Buckinghamshire, UK) or goat anti-rabbit antibody
1:5,000 linked to alkaline phosphatase (Promega, Madison, WI)
for 1h at room temperature. Antibody binding was detected with
the Immobilon western chemiluminescence kit (Millipore, Bill-
erica, MA), using the DIANA III-chemiluminescence detection
system (Raytest, Straubenhardt, Germany). All images were
analyzed using appropriate software (Advanced Image Data
Analyzer, Raytest) to calculate the protein of interest/ß-actin ratio.
Immunohistochemistry
Anesthetized rats were fixed by vascular perfusion through the
left ventricle. The thorax was opened and the fixative was
Table 2. Serum values of phosphate regulatory hormones from vehicle and sirolimus-treated rats after two and seven days of
treatment.
2d 7d
Vehicle Sirolimus Vehicle Sirolimus
PTH (pg/ml) 402.9637.0 177.1635.2{ 333.9643.6 192.5630.5*
FGF23 (pg/ml) 259.0615.4 267.3621.0 249.3619.7 144.2612.2{
Klotho (pg/ml) 466.56134.6 592.66164.5 1110.86264.1 809.16177.3
1,25 Dihydroxycholecalciferol (pg/ml) 123.0610.5 154.569.1 130.5612.2 177.6619.9
Values are means 6 SE, n = 6/group. A summary of blood and urine parameters from rats treated with vehicle and sirolimus for two and seven days is shown. *p,0.05.
{p,0.01. {p,0.001.
doi:10.1371/journal.pone.0039229.t002
Sirolimus Induced Phosphaturia
PLoS ONE | www.plosone.org 4 July 2012 | Volume 7 | Issue 7 | e39229
manually injected through a 50 ml syringe. The fixative consisted
of 3% paraformaldehyde, 0.05% picric acid in 0.1M cacodylate
buffer (pH 7.4; containing 3 mM MgCl2 and adjusted to 300
mosmol/l with sucrose) and 4% hydroxyethyl starch in saline
(HAES sterile; Fresenius, Stans, Switzerland). After ten minutes
the fixative was washed out by perfusion with PBS. Kidneys were
then removed and stored in PBS overnight at 4uC. Coronal slices
of fixed kidneys were then frozen in liquid propane and cooled
with liquid nitrogen and stored 280uC. Serial sections, 5 mm
thick, were cut at 220uC on a cryomicrotome (CM 1850-1-1,
Leica Microsystems, Nussloch, Germany) mounted on thermo
scientific superfrost plus glass slides (Thermo Fischer Scientific Inc,
Braunschweig, Germany), thawed, and kept in cold PBS until
further processing for staining. Before immunofluorescence
staining, sections were pretreated with blocking solution (Normal
Goat Serum 10% in PBS with 0.5% bovine serum albu-
min,0.04%Na-Azide) for 60 min at room temperature. After
blocking sections were incubated with the primary antibody
overnight at 4uC either with a rabbit anti-rat antiserum against the
NaPi-IIa protein [28] diluted 1:1,000 or with an immunopurified
rabbit anti-mouse NaPi-IIc [29] diluted 1:1,500, or a rabbit anti-
rat Pit-2 [2] diluted 1:250. All primary antibodies were diluted in
Figure 3. Sirolimus has no effect on renal phosphate transporter mRNA abundance. Results of the semiquantitative RT-qPCR for NaPi-IIa,
NaPi-IIc, Pit-2, NHE3 and klotho after two and seven days of sirolimus treatment. mRNA abundance for NaPi-IIa, klotho, Pit2 and NHE3 was not
different between groups after two and seven days of sirolimus treatment. NaPi-IIc mRNA abundance was significantly lower in sirolimus treated
animals after two and seven days. * p,0,05.
doi:10.1371/journal.pone.0039229.g003
Sirolimus Induced Phosphaturia
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PBS with 0.5% bovine serum albumin. Sections were then rinsed
three times with PBS and covered for 90 minutes at room
temperature with Alexa Fluor 555 goat–anti-rabbit IgG (1:1,000,
Invitrogen), FITC–phalloidin (Molecular probes, Eugene, OR,
USA, 1:200), and 4,6-diamidino-2-phenylindole (DAPI; Sigma, St
Louis, MO) diluted 1:500. Finally, the sections were rinsed three
times with PBS, cover slipped using DAKO-Glycergel (Dakopatts)
containing 2.5% 1,4-diazabicyclo [2.2.2] octane (Sigma) as a fading
retardant. Immunohistochemistry images were acquired with
a Leica DFC490 charged-coupled device camera attached to
a Leica DM 6000 fluorescence microscope (Leica, Wetzlar,
Germany) using equivalent camera parameters for kidneys sections
stained with the same primary antibody. Pictures were processed
using Adobe Photoshop (overlays).
Statistical analysis
All data are summarized as mean 6 SE and were analyzed
using the unpaired Student’s t- test with p values#0.05 considered
as statistically significant. Urinary phosphate/creatinine ratio
course throughout the experiment was analyzed using a mixed
linear model. We calculated the correlation coefficients for
magnesium, calcium, sodium, chloride and potassium in correla-
tion to phosphate in urine. SAS V9.2 for windows was used as
statistical software (2008 SAS System Inc., Cary, NC, USA).
Results
Animal model, blood and urine parameter
Mean body weight was similar in all groups at the beginning of
the experiment and after two days of treatment with sirolimus but
was significantly lower in sirolimus treated animals after seven days
of treatment (238.2 g 65.9 g vs 195.7 g 65.1 g, p = 0.0003)
(table 1). Sirolimus treatment with 1.5 mg/kg/body weight for two
and seven days resulted in plasma trough levels (mg/l) of 20.962.8
at day 2 and 19.664.5 at day seven. The treatment with the
mTOR inhibitor did not change acid-base homeostasis as
determined by arterial blood gas and urine analysis. Blood glucose
levels did not differ between groups after two days but sirolimus
treated animals exhibited higher serum glucose levels at day seven.
Sirolimus treatment for two and seven days had no effect on
creatinine clearance and serum creatinine levels. Sirolimus
treatment was associated with polyuria indicated by a significantly
higher 24-h urine/body weight (ml/g) after two and seven days
(0.0360.002 vs 0.0660.006, p= 0.004, and 0.0360.004 vs
0.1260.03 p= 0.03, respectively). Accordingly, urine osmolarity
(mOsmol/kg) was significantly decreased in sirolimus treated
animals after seven days but was not significantly decreased after
two days (13256340 vs 15846313, p = 0.2 and 11896217 vs
16756250 p= 0.02, respectively). Serum Na+, Cl2, Ca2+ showed
no significant changes, however, serum K+ was significantly
lowered in sirolimus treated rats after two days (4.660.2 vs
3.460.06, p= 0.0001). Urinary Na+/creatinine ratios ((mmol/l)/
(mmol/l)) were significantly higher after two and seven days
Figure 4. Sirolimus does not alter renal phosphate transpor-
ters. Sirolimus treatment for two and seven days does not alter protein
expression levels of NaPi-IIa, NaPi-IIc, Pit-2, klotho and NHE3 in the
brush border membrane. Brush border membranes or total membrane
protein were prepared from kidneys of sirolimus and vehicle injected
rats (n = 6) and 10 mg of brush border membranes or 35 mg of total
membrane protein were loaded per lane for immunoblotting.
a Membranes were tested for NaPi-IIa, NaPi-IIc, Pit-2, NHE3, and the
aNa+/K+-ATPase subunit and stripped for reprobing with ß-actin to
control for loading. b Densitometric analysis of all immunoblots with
the appropriate software was performed and bands of the proteins of
interest were normalized against ß-actin and the respective vehicle
groups. Sirolimus treatment for two and seven days did not change the
abundance of NaPi-IIa, NaPi-IIc, Pit-2, klotho and NHE3 compared to
vehicle.
doi:10.1371/journal.pone.0039229.g004
Sirolimus Induced Phosphaturia
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treatment (13.262.3 vs 18.664.4, p = 0.02 and 15.761.1 vs
21.564.2, p = 0.02). Cl2/Creatinine ratio ((mmol/l)/(mmol/l))
was significantly higher after seven days (29.262.7 vs 39.665.9,
p = 0.003) but was not different after two days. Mg2+/Creatinine
ratios and Ca2+/Creatinine ratios ((mmol/l)/(mmol/l)) were
significantly higher after two and seven days (magnesium
3.061.3 vs 4.860.8, p= 0.02 and 3.661.2 vs 4.960.4, p = 0.04;
calcium 0.460.1 vs 1.060.4, p= 0.006 and 0.560.1 vs 1.760.8,
p = 0.01). Only very weak overall correlations of urinary
phosphate with magnesium, sodium and chloride, calcium and
potassium were found (Data S1). Whereas sirolimus treatment for
two days did not change urinary pH, animals treated with
sirolimus for seven days excreted a slightly more acidic urine
compared to vehicles (6.3460.05 vs 6.1060.09, p = 0.03).
However, the bicarbonate excretion into the urine remained
unchanged between groups as determined by HCO3
2/creatinine
ratio. Urinary protein excretion was similar between all groups
excluding proteinuria (data not shown). Urinary glucose/creati-
nine ratio ((mmol/l)/(mmol/l)) was significantly higher only after
seven days (0.360.1 vs. 135.46113.6, p= 0.03).
Functional studies of phosphate homeostasis
Urine phosphate/creatinine ratio was higher in sirolimus
treated rats beginning at 24 hours after the first injection and
continued to be higher throughout the whole experiment for two
and seven days (figure 1, p,0.0001) Furthermore, serum
phosphate (mmol/l)) was significantly lower in sirolimus treated
rats after two and seven days (3.360.09 vs 2.860.05, p,0.01 and
3.060.08 vs 2.460.09, p,0.001) (table 1). Moreover Tmp/GFR
(mmol/l) was significantly lower in sirolimus treated rats after two
and seven days (3.060.1 vs 2.560.06, p,0.001 and 2.860.06 vs
2.160.09, p,0.001, respectively). While serum-PTH (pg/ml) was
lower in sirolimus treated rats after two and seven days (403637 vs
177635, p = 0.001 and 334644 vs 193631, p = 0.02), FGF 23
levels (pg/ml) were unchanged after two days but significantly
lower in sirolimus treated rats after seven days (259615 vs
267621 p.0.05 and 249620 vs 144612, p = 0.001). Soluble
klotho serum levels and vitamin D3 serum levels were not
significantly affected by sirolimus treatment (table 2). BBMV 32Pi
uptakes in the absence and presence of phosphonoformic acid
(PFA) were similar in sirolimus and vehicle injected rats after two
and seven days and revealed no different characteristics in
phosphate influx (figure 2). Moreover, incubation of BBMV from
untreated rats with two different sirolimus concentrations, 20ng/
ml and 100ng/ml respectively, during the preparation and uptake
procedure had no effect on Na+-dependent phosphate fluxes
(figure 2).
Renal phosphate regulation on the transcriptional level
Results from semiquantitative RT-qPCR for NaPi-IIa, NaPi-IIc
and Pit-2 revealed only minor changes in mRNA abundance for
these sodium dependent phosphate cotransporters in the PT of
kidneys from sirolimus treated rats (figure 3). In detail mRNA
abundance for NaPi-IIa, Pit2 as well as for klotho was not different
between groups after two and seven days of sirolimus treatment.
NaPi-IIc mRNA abundance was significantly lower in sirolimus
treated animals after two and seven days (160.05 vs 0.660.05,
p = 0.0003 and 160.04 vs 0.660.0, p = 0.0002). Furthermore
NHE3 mRNA levels were not affected by sirolimus treatment.
Our microarray data showing no significant difference between
NaPi-IIa, NaPi-IIc and NHE3 confirm these RT-qPCR results.
Microarray analysis was performed on kidney samples from the
same animals. In total 154 features were identified as significant
differentially expressed when comparing the gene expression
profiles of rat kidneys after seven days of treatment with either
sirolimus or vehicle with a fold change over 1.5, resulting in 139
down-regulated and 15 up-regulated genes in the sirolimus group.
According to PANTHER classification down-regulated transcripts
belong to response to stimulus, metabolic processes, immune
system, transport, and signal transduction. Up-regulated tran-
scripts belong also to response to stimulus, immune system, and
transport but also to blood coagulation and regulation of
vasoconstriction. Interestingly transcriptome analyses revealed
several potential candidate genes that may be involved in tubular
phosphate transport. SLC17A4, a putative sodium-dependent
phosphate transporter protein was significantly down regulated in
sirolimus treated rats compared to vehicle [30].
Renal phosphate regulation on the protein level
Sirolimus treatment for two and seven days did not lead to
a significant alteration in protein expression levels as determined
by immunoblotting for NaPi-IIa, NaPi-IIc, Pit-2, klotho, NHE3,
and the alpha subunit of the Na+/K+-ATPase (figure 4). The
relative protein abundance of NaPi-IIa, NaPi-IIc and Pit-2
remained similar between groups after two and seven days.
Additionally, immunostaining for NaPi-IIa, NaPi-IIc, and Pit-2
did not reveal any difference in transporter distribution and
respective localization at the apical surface of proximal tubule cells
between sirolimus and vehicle treated rats after two and seven days
(figure 5).
Discussion
This study demonstrates that sirolimus causes hypophosphate-
mia and hyperphosphaturia as observed in patients treated with
this immunosuppressant [14]. The rats receiving sirolimus also
recapitulated other side effects such as hyperglycemia and
glucosuria often observed under sirolimus treatment [31]. Our
data indicate that the sirolimus induced urinary phosphate wasting
is not caused by dysfunction of the three currently known
phosphate transporters located in the BBM of the proximal
tubule. Our results furthermore indicate an intact physiological
feedback mechanisms of the phosphate regulating hormones PTH,
1,25 dihydroxycholecalciferol, FGF23 and its cofactor klotho to
counterbalance the renal phosphate loss.
Sirolimus treated rats did not develop signs of general renal
failure or a more generalized Fanconi-like dysfunction of the PT as
indicated by the absence of bicarbonaturia or proteinuria.
Furthermore NHE3 mRNA as well as protein abundance was
not different between groups. The dose of sirolimus applied here is
comparable to that used in similar animal studies [32–34].
Several lines of evidence support the conclusion that sirolimus
did not induce phosphaturia by primarily acting on BBM
phosphate transporters despite a significantly lower mRNA
abundance of NaPi-IIc. i) the rates of Na+-dependent phosphate
uptake into BBMV was not affected by treatment of rats with
Figure 5. Sirolimus has no effect on localization of renal phosphate transporters. Effect of sirolimus treatment for two and seven days on
NaPi-IIa, NaPi-IIc and Pit-2 localization. NaPi-IIa, NaPi-IIc or Pit2 staining (red) was observed in the BBM of early proximal tubules, and colocalized with
b-actin as a marker of the BBM (green) as indicated by the yellow overlay. Nuclei were stained with DAPI (blue). No difference was observed between
animals treated with vehicle or sirolimus for either 2 or 7 days (n = 5 per group). Original magnification 630 x.
doi:10.1371/journal.pone.0039229.g005
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sirolimus or acute incubation in vitro with high concentrations of
sirolimus, ii) mRNA and protein expression of NaPi-IIa and Pit-2
were unaffected by sirolimus treatment. Solely mRNA expression
of NaPi-IIc was significantly down regulated after two and seven
days. However, sirolimus did not alter protein expression of NaPi-
IIc iii) the subcellular localization of these three transporters with
predominant localization in the BBM of the early PT was not
altered, iv) microarray analysis of renal transcripts did not detect
changes in any mRNA related to the known phosphate
transporters or proteins known to be involved in their expression
or activity, and v) hormonal changes are consistent with
compensatory adaptations but not with causing phosphaturia.
Our results are in apparent contradiction with two recent
reports suggesting that the mTOR pathway may regulate the renal
and intestinal phosphate cotransporters NaPi-IIa and NaPi-IIb
[16,17] Both studies describe the in vitro stimulation of NaPi-IIa
and NaPi-IIb induced phosphate transport in Xenopus oocytes by
coexpression of the mTOR kinase and the reversion of the
stimulatory effect by rapamycin. In contrast, our study is
performed in vivo and fails to detect any impact on the renal
NaPi-IIa cotransporter. Moreover, Moz et al demonstrated that
the calcineurin A beta subunit is involved in the regulation of
NaPi-IIa in vivo and required for the normal adaptation of NaPi-
IIa expression in response to changes in dietary phosphate intake
[35]. The requirement of calcineurin A beta may explain the
phosphaturia observed in calcineurin inhibitors such as tacrolimus.
However, sirolimus does not directly affect calcineurin A beta.
It has been previously shown that klotho may exert some
phosphaturic effects independently from FGF23 [36]. However
sirolimus induced phosphaturia in our in vivo rat model did not
alter renal klotho mRNA and protein expression or serum levels.
We also performed whole kidney transcript anaylasis using
microarrays to detect candidate targets of sirolimus that may
participate in the induction of phosphaturia. However, the analysis
of significantly altered transcripts did not reveal any genes with
a clear relation to renal phosphate transporters or their regulation.
Microarray data indicated downregulation of SLC17A4. This
transporter belongs to the SLC17 superfamily of transporters with
subgroups of urate and vesicular gluatamte transporters [37].
Initially several transporters from this family have been assigned as
phosphate transporters due to the induction of phosphate trans-
port when heterologously expressed in Xenopus oocytes [38,39].
More recent experiments identified urate or glutamate as
physiological substrates [37]. However, the substrates of SLC17A3
have not been reported to date and its exact expression pattern not
reported. None of the altered transcripts has been connected to
renal phosphate handling to date. Further analysis of transcripts
affected by sirolimus treatment is required to understand their
biological significance.
The direct target(s) of sirolimus causing phosphaturia remain(s)
elusive. Our results suggest that direct dysregulation of BBM
phosphate transporters can be excluded and that other mechan-
isms must be considered. Two alternative targets might be either
basolateral PT phosphate exit pathways or phosphate transport
mechanisms located in the more distal nephron. Earlier studies
suggested the presence of phosphate absorbing mechanisms in the
distal tubule, however, their functional significance, regulation,
molecular identity, or even existence have remained elusive to date
[40,41]. Completion of phosphate absorption in the PT requires
(a) exit pathway(s) across the basolateral membrane. Only few data
exist analyzing functional properties of the basolateral phosphate
transport mechanisms but the molecular identity of basolateral
phosphate transport proteins is unknown to date [42,43].
Conclusion
Sirolimus induces renal phosphate wasting and the absence of
changes in the expression of all known renal phosphate
transporters and normal BBM phosphate transport rates suggest
an alternative mechansim. Moreover, the regulation of the major
known phosphate regulating hormones, PTH, 1,25 Dihydrox-
ycholecalciferol, FGF23 in response to hypophosphatemia was
intact and suggests rather compensatory adaptation. Sirolimus
might affect other mechanisms that could contribute to overall
renal phosphate handling such as either basolateral exit pathways
for phosphate in the PT or other elusive transport pathways in
downstream nephron segments. Clearly, further studies are needed
to unravel the molecular mechanisms causing sirolimus induced
phosphaturia.
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